Texas Elmiron Pigmentary Maculopathy injury lawyer
For years, Elmiron (pentosan polysulfate sodium) was the only oral medication approved by the FDA for interstitial cystitis, a chronic bladder condition affecting hundreds of thousands of Americans. But by 2020, mounting evidence linked long-term Elmiron use to a distinct form of retinal toxicity now known as pigmentary maculopathy. As a Texas-based legal practice focused on pharmaceutical accountability, we have seen firsthand how this hidden danger robbed patients of their central vision. In 2026, the fight for justice continues in state courts across the Lone Star State, with new clinical guidelines and consolidated litigation reshaping how victims pursue compensation.
Janssen's Elmiron: The 2020 VA Study That Changed Ophthalmology
The turning point came in June 2020, when researchers at the Veterans Affairs Medical Center in Portland published a landmark study in the journal Ophthalmology. They found that 11 of 91 patients who took Elmiron for at least 15 years showed unmistakable signs of pigmentary maculopathy—a condition that mimics age-related macular degeneration but strikes decades earlier. Dr. Nieraj Jain, the lead author, noted that the retinal damage was "dose-dependent" and often irreversible. By 2025, the American Academy of Ophthalmology had updated its screening protocols, recommending baseline retinal exams for any patient starting Elmiron. Despite this, Janssen Pharmaceuticals—the drug's manufacturer—did not update its label to include a black-box warning until late 2023, years after the first whistleblower reports emerged.
"The latency period for Elmiron toxicity is insidious. Patients often don't notice vision changes until 10 to 15 years of cumulative use, by which point the retinal pigment epithelium is already compromised." — Dr. Nieraj Jain, Portland VA Medical Center, 2020 study. For full context, see the original study at PubMed and the archived legal case summaries at Biblesta.com archive.
Texas Multidistrict Litigation MDL 3057: Key Rulings and Settlement Timelines
As of early 2026, the federal multidistrict litigation (MDL 3057) in the District of New Jersey has overseen over 2,200 active claims. However, Texas plaintiffs have a distinct advantage: the state's two-year statute of limitations for personal injury claims begins ticking from the date the patient "knew or should have known" the cause of their vision loss, not from the date of first prescription. This nuance has allowed many Houston and Dallas residents to file late claims after receiving a definitive diagnosis from a retinal specialist. Below is a summary of the current litigation landscape:
| Phase | Date | Key Event | Impact on Texas Cases |
|---|---|---|---|
| Initial Filing | Sept 2020 | First Elmiron MDL established | Texas cases consolidated into New Jersey |
| Bellwether Trials | Jan–Mar 2025 | Three trials resulted in two plaintiff verdicts, one defense win | Average award: $2.4M per plaintiff |
| Global Settlement Talks | Nov 2025 | Janssen offered $890M to settle 90% of claims | Texas plaintiffs with bilateral maculopathy offered $150K–$500K |
| Current Status | Feb 2026 | Opt-in deadline extended to June 2026 | New Texas cases still accepted under MDL |
Why Texas Patients Need a Local Attorney for the 2026 Opt-In Window
The current global settlement offer from Janssen requires plaintiffs to release all claims in exchange for a tiered payout based on retinal imaging evidence. But Texas law imposes unique hurdles: the Texas Deceptive Trade Practices Act (DTPA) can be used to pursue treble damages if the manufacturer failed to warn physicians, and Texas courts have historically been skeptical of "foreign" mass tort settlements that try to limit discovery. Our firm has successfully argued that Janssen's internal emails from 2015—showing the company knew about retinal toxicity but suppressed it—are admissible under Texas Rule of Evidence 801(e)(2). This has allowed us to bypass the MDL's discovery limits in several state court cases.
- Statute of Limitations: Texas gives you two years from diagnosis. If you stopped taking Elmiron before 2020, your clock may still be open if you only learned of the link in 2024 or later.
- Medical Records: We require a retinal OCT scan showing "hyperautofluorescent spots" at the level of the RPE, plus a history of at least 500 grams of cumulative Elmiron use (roughly 7 years of daily dosing).
- No Upfront Costs: All Texas Elmiron cases are handled on a contingency basis. We advance the cost of expert ophthalmologist testimony and medical chart reviews.
- Coordination with Your Urologist: Many patients still need alternative treatment for interstitial cystitis. We work with Texas urology groups to ensure your bladder care continues uninterrupted.
The window for joining the MDL settlement closes in June 2026. If you or a loved one took Elmiron for interstitial cystitis and now struggle with blurred vision, difficulty reading, or sensitivity to light, contact our office immediately. We will obtain your pharmacy records, schedule a retinal exam with a board-certified specialist, and file your claim before the deadline. The evidence is overwhelming: Janssen knew, and Texas patients deserve full compensation for a lifetime of lost vision.